#### 1 Title

- 2 Strategic validation of variants of uncertain significance in ECHS1 genetic testing
- 3

#### 4 **Running title**

- 5 VUS validation in ECHS1 genetic testing
- 6

#### 7 Authors

- Yoshihito Kishita<sup>1,2,12</sup>, Ayumu Sugiura<sup>2,12</sup>, Takanori Onuki<sup>3</sup>, Tomohiro Ebihara<sup>4</sup>, Tetsuro 8
- 9 Matsuhashi<sup>3</sup>, Masaru Shimura<sup>3</sup>, Takuya Fushimi<sup>3</sup>, Noriko Ichino<sup>2</sup>, Yoshie Nagatakidani<sup>1</sup>,
- 10 Hitomi Nishihata<sup>1</sup>, Kazuhiro R Nitta<sup>2</sup>, Yukiko Yatsuka<sup>2</sup>, Atsuko Imai-Okazaki<sup>2</sup>, Yibo Wu<sup>5,6</sup>,
- Hitoshi Osaka<sup>7</sup>, Akira Ohtake<sup>8,9</sup>, Kei Murayama<sup>3,10</sup>, Yasushi Okazaki<sup>2,11,\*</sup> 11
- 12

#### 13 Affiliations

- 14 <sup>1</sup>Department of Life Science, Faculty of Science and Engineering, Kindai University,
- 15 Osaka, Japan
- 16 <sup>2</sup>Diagnostics and Therapeutics of Intractable Diseases, Intractable Disease Research
- 17 Center, Juntendo University, Graduate School of Medicine, Japan
- 18 <sup>3</sup>Department of Metabolism, Chiba Children's Hospital, Chiba, Japan
- 19 <sup>4</sup>Department of Neonatology, Chiba Children's Hospital, Chiba, Japan
- 20 <sup>5</sup>University of Geneva, Geneva, Switzerland.
- 21 <sup>6</sup>YCI Laboratory for Next-Generation Proteomics, RIKEN Center of Integrative Medical
- 22 Sciences, Kanagawa, Japan
- 23 <sup>7</sup>Department of Pediatrics, Jichi Medical University, Tochigi, Japan
- 24 <sup>8</sup>Department of Pediatrics & Clinical Genomics, Faculty of Medicine, Saitama Medical
- 25 University, Saitama, Japan
- 26 <sup>9</sup>Center for Intractable Diseases, Saitama Medical University Hospital, Saitama, Japan
- 27 <sup>10</sup>Center for Medical Genetics, Chiba Children's Hospital, Chiba, Japan
- 28 <sup>11</sup>Laboratory for Comprehensive Genomic Analysis, RIKEN Center for Integrative
- 29 Medical Sciences, Yokohama, Kanagawa, Japan
- 30 <sup>12</sup>These authors contributed equally
- 31 \*Corresponding author: ya-okazaki@juntendo.ac.jp
- 32

#### 1 Abstract

- 2 ECHS1 is the causative gene for mitochondrial short-chain enoyl-CoA hydratase 1 3 deficiency. While genetic analysis studies have diagnosed numerous cases with ECHS1 4 variants, the increasing number of variants of uncertain significance (VUS) in genetic 5 diagnosis is a major problem. Therefore, we constructed an assay system to verify VUS 6 function. A high-throughput assay using ECHS1 knockout cells was performed to index 7 these phenotypes by expressing cDNAs containing VUS. The functional validation of 8 VUS identified novel variants causing loss of ECHS1 function. Moreover, we identified 9 cases with functional ECHS1 defects through multi-omics analysis. We identified a 10 synonymous substitution, p.P163=, and candidate pathogenic variants in the above 11 validation experiments. In summary, this study uncovered new ECHS1 cases based on 12 VUS validation and omics analysis; these analyses are applicable to functional 13 evaluation of other genes associated with mitochondrial disease. 14
- 15 Keywords

16 Variants of uncertain significance, Mitochondrial disease, RNA-seq, High-throughput

17 assay, Multi-omics

#### 1 Introduction

2 ECHS1 encodes short-chain enoyl-CoA hydratase 1 (SCEH), responsible for the 3 degradation of branched chain amino acids and fatty acids (Sharpe & McKenzie, 2018). 4 Abnormalities in valine metabolism particularly impact the pathogenesis of SCEH 5 deficiency (MIM #616277); accumulation of valine metabolites such as S-(2-carbox-6 ypropyl) cysteine (SCPC) and S-(2-carboxypropyl) cysteamine (SCPCM) derived from 7 methacrylyl-CoA, and S-(2-carboxyethyl) cysteine (SCEC), S-(2-carboxyethyl) 8 cysteamine (SCECM), and 2-methyl-2,3-dihydroxybutyric acid (MDHB), derived from 9 acryloyl-CoA, is often observed (Peters et al, 2014). Mutations in ECHS1 mainly cause 10 Leigh encephalopathy with patients presenting elevated plasma lactate and brain 11 magnetic resonance imaging (MRI) abnormalities (Peters et al, 2015; Yamada et al, 12 2015; Haack et al, 2015a; Sakai et al, 2015; Tetreault et al, 2015). In addition, 13 mitochondrial respiratory chain complex abnormalities have also been reported to cause mitochondrial dysfunction in cases with ECHS1 mutations (Sakai et al, 2015; Haack et 14 15 al, 2015a; Tetreault et al, 2015). Numerous Japanese cases with ECHS1 mutations have 16 also been reported (Sakai et al, 2015; Haack et al, 2015a; Yamada et al, 2015; Ogawa 17 et al, 2017, 2020). Numerous ECHS1 variants have been reported, among which, 18 pathogenic variants exist in various genetic regions. A variant frequently reported in 19 Asians is Asn59Ser. The expansion in the clinic of genetic testing has resulted in the 20 rapid accumulation of variants of uncertain significance (VUS). Mitochondrial diseases 21 are no exception, and the VUS number in ECHS1 is increasing. On the other hand, 22 recent studies have also shown that a valine-restricted diet is effective for cases with 23 ECHS1 mutations (Yang & Yu, 2020; Sato-Shirai et al, 2021). Quick diagnosis is 24 important for early treatment of SCEH deficiency.

25 Recently, various approaches have been tried to solve VUS. Functional analysis using 26 cultured cells and model organisms is a powerful validation method, providing strong 27 evidence of pathogenicity according to the American College of Medical Genetics and 28 Genomics (ACMG) guidelines (Richards et al, 2015). Especially, high-throughput assays 29 and assay methods combining CRISPR/Cas9 and genome-sequencing technologies are 30 being used for VUS verification in cancer-causing genes (Findlay et al, 2018; Kweon et 31 al, 2020). Although VUS have been validated for IVD, ACADVL, and ACAD9, all 32 causative genes of inborn errors of metabolism (D'Annibale et al, 2021; Xia et al, 2021; 33 D'Annibale et al, 2022), there is little research on VUS verification in rare diseases.

34 In this study, we focused on VUS in ECHS1, common in many cases of mitochondrial 35 diseases (Kohda et al. 2016; Ogawa et al. 2017, 2020). In Japan, Tohoku Medical 36 Megabank has a genome project for healthy subjects (Tadaka et al, 2019, 2021). In

- 1 recessive diseases, the causative variant is often present at a certain frequency within a
- 2 given race. Therefore, in addition to the VUS found in previous our studies of patients
- 3 with mitochondrial diseases, we conducted a variant validation of rare variants registered
- 4 in the Japanese Multi-Omics Reference Panel (jMorp).
- 5 Here, we constructed an assay system with ATP measurement using cells deficient in
- 6 the ECHS1 gene for systematic VUS verification and validation of heterozygotic variants.
- 7 Furthermore, we found a novel ECHS1 variant by multi-omics analysis. Coincidentally,
- 8 the newly found variants were verified by the assay system as being caused by ECHS1.
- 9

#### 10 Results

#### 11 Cases with ECHS1 variants

12 In previous genomic studies, gene panel sequencing and whole exome sequencing led 13 to the discovery of 15 variants in *ECHS1* cases (Table 1). In Japanese people, the most frequently identified variant was Asn59Ser, followed by Ala2Val (Haack et al, 2015b; 14 15 Sakai *et al*, 2015; Ogawa *et al*, 2020) (Table 1 and Fig. 1). These variants are common 16 in other Asian cases: the allele frequencies of Asn59Ser and Ala2Val are 0.0005769 and 17 0.0001927 in the gnomAD v3.1.2 East Asian, respectively. Several of these cases also 18 had VUS in ClinVar (as of 20220715, and the same afterhere), such as Met1Val and 19 Leu8Pro (Ogawa et al, 2017; Uchino et al, 2019). In addition, we also found 20 heterozygous variants in ECHS1 with conflicting interpretations of pathogenicity 21 (Thr266Ala and Ala278Thr), VUS (Arg272GIn), or unreported (Ala268Thr). All these 22 variants are rare and may be disease-causing, but no experimental verification of the 23 variants has been performed so far. Variants with low allele frequency have been 24 identified, and a number of them have been designated as VUS. Accurate and guick 25 interpretation of these variants is essential for improved diagnosis.

26

#### 27 VUS validation in ECHS1

28 To perform VUS validation of ECHS1, we first generated cells deficient in the ECHS1 29 gene by targeting ECHS1 using the CRISPR/Cas9 system in HEK293FT cells. The 30 ECHS1 KO cell line had an in-frame deletion of 18 bases in exon 2 of the ECHS1 gene 31 (Fig. 2A). This in-frame deletion resulted in loss of ECHS1 mRNA and protein, as 32 confirmed by qRT-PCR and western blotting (Fig. 2B). We also detected abnormalities 33 in the mitochondrial function in ECHS1 KO cells. In galactose medium, ATP production 34 is largely dependent on mitochondrial respiration (Robinson et al, 1992). Accordingly, we 35 measured ATP levels of wild-type (WT) and ECHS1 KO cells after incubation in glucose 36 and galactose media. The ratio of ATP levels under galactose and glucose conditions

1 was stable, and no significant difference was observed between ECHS1 KO and WT 2 cells under these conditions (Fig. 2C). The cellular toxicity of ECHS1 deficiency is due 3 to accumulation of intermediates in valine metabolism. That explains why a valine-4 restricted diet is recommended to patients harboring ECHS1 pathogenic variants (Sato-5 Shirai et al, 2021). Consistently, valine addition to the galactose medium lead to further 6 reduced ATP level in ECHS1 KO cells, in a dose-dependent manner (Fig. 2D). These 7 results suggest that the abnormal mitochondrial function in ECHS1 KO cells results from 8 the abnormal valine metabolism, as shown in human patients, making it a suitable model 9 to validate VUS of ECHS1. Accordingly, we performed a functional verification of VUS 10 using ECHS1 KO cells expressing VUS. 11 First, variants identified from previous genomic studies and from Morp were selected for 12 functional validation. The targets were 15 variants identified by our genome analysis and 13 six rare variants registered in jMorp (4.7KJPN released on 20190902; Fig. 1 and Table

S1). The Leu8Pro and Asn59Ser variants were found in our patients as well as registered 14 15 in jMorp (4.7KJPN). Other four variants were not identified in our genome analysis of 16 mitochondrial disease patients. ECHS1 is a mitochondria-localized protein with a 17 mitochondrial targeting sequence (MTS) at the N-terminal. Four variants were located at 18 the translation initiation site and the MTS. We compared ECHS1 KO cells transfected 19 with an empty vector and ECHS1 WT cDNA to ECHS1 KO cells transfected with an 20 ECHS1 gene including VUS.

21 Exogenously expressed ECHS1 shows uncleaved and cleaved forms (Fig. 3A, single 22 and double asterisks, respectively). Some variants were dominantly expressed in an 23 uncleaved form. Further, we found a significant decrease in the expression level of 24 variants in the MTS and at leucine 145 (Fig. 3A).

25 Next, we examined VUS functions in the mitochondria. ECHS1 WT expression restored 26 ATP levels in ECHS1 KO cells (Fig. 3B). The ATP expression of KO cells transfected with 27 each variant was compared with that for KO cells transfected with empty vector or 28 transfected with WT vector; changes in ATP levels were evaluated by one-way ANOVA 29 followed by Dunnet's test (Fig. 3C). In addition to Ala2Val and Asn59S, reported as 30 pathogenic variants, the two VUS with altered start codons failed to restore ATP levels 31 probably due to significantly reduced protein expression (Fig. 3B). A marked down-32 regulation in protein levels was observed, with Leu8Pro showing a significant reduction 33 in the lower band considered to correspond to mature ECHS1 (Fig. 3A). His119GIn, 34 Pro163Leu, Ala268Thr, and Ala278Thr variants had higher expression levels, but failed 35 to fully improve ATP levels equivalent to WT, suggesting that these variants were 36 deleterious (Fig. 3B).

medRxiv preprint doi: https://doi.org/10.1101/2022.10.09.22280834; this version posted October 13, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in

perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

1 Although Leu8Pro and Phe33Ser were reported as pathogenic variants (Kohda et al, 2 2016; Uchino et al, 2019), ATP assays demonstrate a mild functional decline. Since 3 Leu8Pro and Phe33Ser were identified as a compound heterozygote with Asn59Ser, a 4 nonfunctional variant (Fig. 3B), we hypothesized that Leu8Pro and Phe33Ser might be 5 mild deleterious variants capable of restoring KO cells but not KO cells expressing highly 6 toxic variants. To test this hypothesis, we reproduced compound heterozygous 7 genotypes by transfecting ECHS1 KO cells with two different variants (Fig. 4A). The ATP 8 assay demonstrated that WT restored KO cells upon co-transfection with Asn59Ser, 9 whereas, as expected, all three variants tested did not show recovery (Fig. 4B and C). 10 Our system is valuable to validate the pathogenic nature of the compound heterozygous 11 state.

12

#### 13 Validation of ECHS1 variants from omics analysis

14 In case 1, a Thr266Pro variant was identified; in case 2, an Ala268Thr variant was 15 identified; in cases 3 and 4, a Ala278Thr variant was identified; in case 5, an Ala278Val 16 variant was identified (Table 2, Fig. S2). In addition, these cases also had a Pro163= 17 variant, identified in a Samoan family and a very frequent variant (0.01156) in gnomAD 18 v3.1.2 East Asian populations, and suggested to exhibit splicing abnormalities (Simon et 19 al, 2021). In the present study, RNA-seq analysis was performed on case 1 and case 4. 20 Then, we identified sequence reads showing exon skipping as consequence of the 21 Pro163= variant (Fig. 5A). To examine whether exon skipping actually increased in cases 22 with Pro163=, we plotted RNA-seq counts of the ECHS1 gene and the number of 23 detected reads showing exon skipping (Fig. 5B). We analyzed 26 RNA-seg data, 24 including case 1 and case 4, as well as one case with heterozygous Pro163=; exon 25 skipping increased in these samples. In addition, after counting the allele numbers at the 26 Thr266Pro and Ala278Thr variant positions showed a bias in allele expression (Fig. 5C). 27 This indicates that the significantly reduced expression of alleles with Pro163= in case 1 28 and case 4 fibroblasts. Furthermore, proteome analysis in case 1 fibroblasts confirmed 29 a significant decrease in ECHS1 expression (Fig. 6A). In addition, protein expression in 30 case 1 fibroblasts was confirmed by sodium dodecyl sulfate polyacrylamide gel 31 electrophoresis (SDS-PAGE) followed by Western blot (WB), revealing a marked decrease 32 in protein expression (Fig. 6B). Furthermore, previous studies experimentally 33 demonstrated that case 4 leads to decreased ECHS1 expression and enzymatic activity. 34 as well as accumulation of intermediate products of valine metabolism (Kuwajima et al, 35 2021). We here concluded that and non-synonymous substitution combinations are 36 disease-causing in these cases.

#### 1

#### 2 Discussion

3 ECHS1 is one of the most frequent genes found in patients with mitochondrial diseases. 4 In addition to our genetic study(Haack et al, 2015b; Ogawa et al, 2017, 2020), ECHS1 5 has been reported as a frequent cause of mitochondrial disease in genetic studies of 6 Leigh encephalopathy in Asian countries such as China(Stenton et al, 2022) and 7 Korea(Lee et al, 2020). The length of the coding region is 873 bp. About 250 variants 8 have been reported in ClinVar, of which about 40 are pathogenic/likely pathogenic and 9 nearly 80 have been registered as VUS or with conflicting interpretations of pathogenicity. 10 However, the molecular mechanism by which *ECHS1* variants cause disease is poorly 11 understood. In this study, we established a system to functionally validate ECHS1 12 variants, finding some potential pathogenic variants.

13 Resolving VUS is a major challenge in various diseases, because VUS continue to 14 accumulate under the circumstances where genome analysis is becoming more 15 common. Genome sequence projects in healthy individuals have revealed allele 16 frequencies in various races. The accumulation of genome analysis information is 17 expected to lead to the discovery of novel pathogenic variants, since rare variants also 18 found in healthy individuals can be pathogenic. Against this background, it may be 19 possible to make a proactive evaluation of variants not yet been associated with disease. 20 Based on the above, we could identify novel pathogenic variants in this study. 21 Furthermore, the combination of RNA-seq, proteomics and conventional genomic 22 analysis enabled a reliable diagnosis.

23 ECHS1 is a nuclear-encoded gene transported to mitochondria by the MTS(Burgin & 24 McKenzie, 2020). MTS locates at the N-terminus and is cleaved in mitochondria by 25 mitochondrial proteases(Vaca Jacome et al, 2015). There are three points involved in 26 pathogenicity: 1) expression, 2) location, and 3) function. It was reported that ECHS1 is 27 degraded through ubiguitin-proteasome pathway in cancer cells (PMID: 34615856). As 28 shown in Fig. 2A, Met1Ala, Met1Thr, and Ala2Val were weakly expressed. Consistently, 29 these variants failed to restore ATP decrease in ECHS1 KO cells. Since inhibition of 30 proteasome degradation by MG132 had no effect on the protein level of all ECHS1 31 variants tested in this study (Fig. S1), these substitutions may alter the expression level 32 at the transcriptional or translational level. The Leu8Pro variant was detected dominantly 33 in the uncleaved form (Fig. 3A), suggesting mis-targeting to mitochondria. Leu145Pro 34 was also weakly expressed, but increased expression with higher amount of transfection 35 did not restore. As with Asn54Ser, Leu145Pro is a functionally disrupted variant. 36 Interestingly, Leu145Pro, a variant reported only in jMorp and not previously identified in

1 patients with the disease, had a high molecular weight. It is expected to be reported in

2 Japanese case with this variant. We propose that those who identify variants in ECHS1

3 by genetic test will refer to our variant evaluation study as evidence and that this will lead

4 to a solution to the cause of the disease in the future.

5 Leu8Pro and Phe33Ser, considered "Likely benign" variants from VUS validation 6 experiments (Fig. 3B and C), were validated by co-expressing with the Asn59Ser variant 7 (Fig. 4B and C). By validating the assumption of complex heterozygosity in combination 8 with a pathogenic variant, we could obtain data accurately reflecting the functional 9 evaluation of hypomorphic variants. The assay was effective for variants in the borders, 10 for which very subtle validation results were obtained. Despite its higher experimental 11 complexity, the assay can be performed while maintaining the conventional throughput, 12 and the validation targets can be expanded. In our reported ECHS1 mutant cases, the 13 most common combination of is Asn59Ser and Ala2Val. However, since Asn59Ser has a 14 higher allele frequency than Ala2Val, cases homozygous for Asn59Ser should be more 15 frequent; however, no patients homozygous for Asn59Ser have been found. This 16 suggests that Asn59Ser may be so harmful that in homozygosity it may result in severe 17 developmental abnormalities in the prenatal period. The high number of Asn59Ser and 18 Ala2Val combinations may be due to Ala2Val having a smaller functional loss than 19 Asn59Ser, as shown experimentally in this study. Asn59Ser is only viable in a compound 20 heterozygous state with less toxic variants. The combination with milder variants such 21 as Leu8Pro and Phe33Ser, verified in this study, might allow normal development until 22 birth. In other words, this combined assay could first accurately indicate functional 23 abnormalities for variants with abnormalities intermediate between normal and 24 completely defective, being a very effective and essential method for variant evaluation. 25 Mostly, in silico predictions and experimental validation of most variants are comparable. 26 On the other hand, silico predictions for some variants differ from our validation 27 experiments; therefore, validation experiments are important for such variants. For 28 example, Ala2Val, already been reported as pathogenic, was not highly damaging in in 29 silico predictions (Table S1). However, the validation results suggest that although the 30 experimental data indicate an effect on protein gene expression itself, the functional 31 effect may not be as significant. A similar trend was observed for Leu8Pro, expected to 32 have a significant effect on protein localization but relatively little effect on protein function. 33 His119GIn was also rated mostly tolerant or benign in silico, but experimental validation 34 suggested that the variant affects gene function. The major achievement of this study is 35 providing quantitative experimental validation data for each variant on the same 36 functional platform. We are expanding the validation of other genes; in particular, VUS

validation of genes involved in respiratory chain complex I confirmed this to be a
 reproducible and efficient analysis.

3 In this validation, we focused on variants specific to Japanese and Asian populations. 4 Naturally, this should be further expanded to include variants from other ethnicities. Our 5 assay system is based on a very simple method and can easily be expanded to other 6 VUS, by including gnomAD and ClinVar variants. In the present study, VUS was verified 7 for jMorp (4.7KJPN) variants, but since then, the jMorp data has been updated and the 8 number of registrations has increased. While planning our validation experiment, the 9 variant data of 4.7K JPN were registered, from which we extracted variants with very low 10 allele frequencies (Table S2). However, there are now 38K JPN, with 20 more 11 registrations from our validated variants. The data is being updated at an accelerated 12 pace, with 14KJPN in 2021 and 38KJPN in 2022. Given the constant updates to the 13 database, it is important to verify these variants in the future.

14 ECHS1 protein loss is considered to have a threshold of 30–40% for disease(Simon et 15 al, 2021). This is shown by the analysis with Pro163= and Ala278Thr from the study of 16 Simon et al. Those homozygous for Pro163= did not develop the disease, despite 17 showing a protein expression around 40%. On the other hand, the combination of 18 Pro163= and Ala278Thr showed <30% protein expression and developed the disease. 19 Ala278Thr is considered highly toxic, as it was found to be deleterious in the VUS 20 validation experiment. Although Ala278Val has not been validated, we think it likely to be 21 as deleterious as Ala278Thr since many scores in silico also indicated damaging effects. 22 For Thr266Pro, no significant decrease in ATP levels was observed in VUS validation. 23 However, abnormalities at the protein level were evident from the proteome and 24 immunoblotting. VUS expression experiments with the Thr266Pro variant also showed 25 reduced ECHS1 expression (Fig. 3A). Considering these results, Thr266Pro might have 26 less functional loss and more impact on protein expression. In addition, the forced 27 expression system showed a protein decrease not expected to significantly reduce ATP 28 levels. In protein expression validation (Fig. S1), the amount of mature ECHS1 29 synthesized from Thr266Pro was lower than that of immature ECHS1, suggesting that 30 this variant has a significant effect on protein expression and maturation. For Ala268Thr, 31 a mild decrease in ATP levels was observed. Since the value of Ala268Thr was similar 32 to that of Pro163Leu, reported as likely pathogenic in ClinVar, Ala268Thr was considered 33 to have an effect on protein function. Case 2 with the Ala268Thr variant had later onset 34 and milder symptoms than other ECHS1 cases, suggesting that the variant itself has a milder effect. Pro163=, despite its high allele frequency [0.01156 in gnomAD v3.1.2 East 35 36 Asian, 0.00789 in the jMorp (38KJPN)], is a possible causative variant; its combination

1 with other pathogenic variants leads to disease development. We found four cases with 2 Pro163= and other rare variant in this study. There have been very few reports of such 3 a high frequency variant in studies of mitochondrial diseases; this variant might be 4 responsible for the increased frequency of cases with ECHS1 mutations. However, 5 variants without amino acid substitutions have been overlooked as benign in previous 6 genetic diagnosis. Given the high potential number of patients with Pro163=, it is 7 expected that the number of cases with Pro163= will further increase because of our 8 findings.

9 Our VUS verification system has some limitations. Even pathogenic variants may be 10 missed in this experimental system. In fact, Pro163Leu, registered as likely pathogenic 11 in ClinVar, showed a mild score. Thus, variants with intermediate ratings could be 12 pathogenic. In such cases, it would be necessary to validate them using an assay system 13 that assumes compound heterozygosity. Moreover, since this is a forced expression 14 system, variants that cause protein stability or splicing abnormalities may be missed. To 15 extract these variants, other assay systems and functional experiments using patient 16 specimens are required.

17

### 18 Materials and methods

19 Cell culture and knockout cell generation

20 Cells were cultured at 37°C and 5% CO<sub>2</sub> in Dulbecco's modified Eagle's medium (DMEM

with 4.5 g/L glucose; Nacalai Tesque) supplemented with 10% fetal bovine serum and
1% penicillin–streptomycin.

23 Single guide RNAs (sgRNAs) were designed using CRISPRdirect software (Naito et al, 24 2015).he target sequence was as follows: 5'-GGGCCTTGGGGCGGTTCAGT-3'. gRNA 25 oligonucleotides were inserted into a pSpCas9(BB)-2A-Puro (PX459) V2.0 (Addgene 26 62988) plasmid as previously described(Ran et al, 2013). HEK293FT cells were 27 transfected with PX459 including ECHS1 targeted sgRNA. Cells were selected using 2 28 µg/mL puromycin and single cells were isolated. Genomic DNA was extracted from 29 isolated cells, and sgRNA target sites were amplified using KOD FX Neo (Toyobo). 30 Primer sequences are as follows: 5'-CCCATGACCGTCTTCACTCG-3' and 5'-31 ACATCCCTTCCCCCACTCTC-3'. PCR products were purified and directly sequenced.

32

### 33 Vector construction

cDNA of *ECHS1* (NM\_00492) WT and VUS were synthetized and inserted into
 pCDNA3.1 Lifect-EGFP (Addgene 67303) with HindIII and Xbal sites by GENEWIZ/
 Azenta.

1

#### 2 ATP assay

3 HEK293FT WT or ECHS1 knockout cells were seeded in a collagen-coated 96-well plate (354650, Corning, AZ, USA) at  $1 \times 10^4$  cells/well with growth medium containing 25 mM 4 5 glucose. For VUS validation, ECHS1 knockout cells were transfected with 20 ng of 6 expression vectors encoding WT or ECHS1 variants. One day after plating or 7 transfection, the medium was replaced with 25 mM glucose or 10 mM galactose medium 8 supplemented with dialyzed 10% fetal bovine serum (04-011-1A, Biological industries, 9 KibbutzBeit-Haemek, Israel) and L-valine (13046-62, Nacalai Tesque, Kyoto, Japan). 10 Four days after culture in galactose or glucose medium, the ATP content was measured 11 using the CellTiter-Glo® Luminescent Cell Viability Assay kit (Promega) with a VICTOR 12 Nivo multimode microplate reader (PerkinElmer, MA, USA).

13

#### 14 RNA-seq

15 RNA was purified from fibroblasts by the Maxwell RSC simplyRNA Cells Kit and a 16 Maxwell RSC Instrument (Promega). After guality check by Agilent 2100 and Qubit 2.0. 17 the mRNA was enriched using oligo(dT) beads and rRNA removed using the Ribo-Zero 18 kit. The mRNA was fragmented randomly by adding fragmentation buffer; then, cDNA 19 was synthesized by using the mRNA template and random hexamers primers, followed 20 by addition of a custom second-strand synthesis buffer (Illumina), dNTPs, RNase H and 21 DNA polymerase I to initiate second-strand synthesis. Second, after a terminal repair, A 22 ligation, and sequencing adaptor ligation, the double-stranded cDNA library was 23 completed through size selection and PCR enrichment. Sequencing was performed 24 using 150-bp paired-end reads on a NovaSeq6000 (Illumina). Fastg files were aligned to 25 the GRCh38/hg38 genome by STAR. Gene read counts were quantified by STAR 26 quantMode GeneCounts function. The aligned BAM files were loaded into the Integrated 27 Genomics Viewer and visualized using a Sashimi plot for mRNA splicing analysis.

28

#### 29 qRT-PCR

30 RNA was isolated from culture fibroblasts using FastGene RNA Basic Kit. The isolated 31 RNA was reverse-transcribed to cDNA using ReverTra Ace® gPCR RT Master Mix 32 (TOYOBO) according to manufacturer's instructions. The synthesized cDNA was used 33 as a template for gRT-PCR in a 7500 Fast Real-Time PCR System (Thermo Fisher 34 Scientific) using THUNDERBIRD® Probe One-step qRT-PCR Kit (TOYOBO). Primer 35 sequences are as follows: ECHS1-F, 5'-GTCTTCAGGGCCTGGTTGAG-3', ECHS1-R, 36 5'-CTGTGCAAACTGGGCCTTCT-3', ACTB-F, 5'-GCGAGAAGATGACCCAGATC-3',

### 1 ACTB-R, 5'-GGATAGCACAGCCTGGATAG-3'.

2

### 3 Sanger sequencing

The *ECHS1* variants of patients and family members were sequenced by Sanger sequencing. PCR products were directly sequenced using BigDye v3.1 Terminators (Applied Biosystem, ThemoFisher Scientific) or SupreDye v3.1 reagent (Edge BioSystems) and ABI 3130XL (Applied Biosystems, ThemoFisher Scientific).

8

### 9 Proteome

Samples from fibroblasts were prepared as described previously (Borna *et al*, 2019). The samples were measured in both data-dependent and data-independent modes performed on the Q-Exactive Plus mass spectrometer (Thermo Fisher Scientific) as previously described (Borna *et al*, 2019). Finally, 5,979 proteins were detected in 16 samples including two healthy controls and 14 mitochondrial disease patients. Then, outlier protein expression analysis was performed using OUTRIDER (Brechtmann *et al*, 2018).

17

### 18 Immunoblotting analysis

19 SDS-PAGE and western blot were performed as previously described (Kohda et al, 20 2016). To isolate mitochondria, cell pellets were suspended in mitochondria isolation 21 buffer A (220 mM mannitol, 20 mM HEPES, 70 mM sucrose, 1 mM EDTA, pH 7.4, 2 22 mg/mL bovine serum albumin, 1× protease inhibitor cocktail) and homogenized with 20 23 strokes on ice. Homogenates were separated into cytosolic and nuclear fractions after 24 centrifugation at 700 g for 5 min at 4°C. The supernatants were centrifuged at 10,000 g 25 for 10 min at 4°C. Mitochondrial pellets were rinsed twice with mitochondria isolation 26 buffer B (220 mM mannitol, 20 mM HEPES, 70 mM sucrose, 1 mM EDTA, pH 7.4, 1× 27 protease inhibitor cocktail). Then, mitochondrial protein levels were determined using a 28 bicinchoninic acid assay. For SDS-PAGE analyses, enriched mitochondria were 29 solubilized in RIPA buffer (Nacalai Tesque, Japan) and denatured for 5 min at 95°C. 30 Prepared samples were separated by electrophoresis on 10% or 15% SDS-PAGE gels, 31 depending on the size of the detected protein. Each antibody was obtained as follows; 32 ECHS1 (11305-1-AP, Proteintech, IL, USA), GAPDH (G9545, Sigma-Aldrich), beta-actin 33 (A5441, Sigma-Aldrich).

34

### 35 Ethics statement

36 The studies were approved by the regional Ethics Committees at Juntendo University,

1 Saitama Medical University, and Chiba Children's Hospital, Kindai University. We

obtained written informed consent from the parents. All methods were performed in
 accordance with relevant guidelines and regulations.

4

### 5 Statistics

Data are expressed as the mean ± SEM. The statistical significance of differences was
determined by one-way ANOVA followed by Dunnet's test using Prism 9 (GraphPad
Software Inc., CA, USA).

- 9
- 10

## 11 Data availability

12 Raw data are available from the corresponding author upon reasonable request. ECHS1

13 knockout cells can also be distributed. Some genomic information that could be used to

14 identify individuals cannot be shared due to ethical restrictions.

15

### 16 Acknowledgments

17 We thank the family for their participation in the research presented here and the Laboratory of Molecular and Biochemical Research, Biomedical Research Core 18 19 Facilities, Juntendo University Graduate School of Medicine, and Kasumi Kanai for 20 technical assistance. This work was supported by a grant for the Practical Research 21 Project for Rare/Intractable Diseases from AMED to H.O., K.M., Y.O. and A.O. (Fund ID: 22 JP21im0210625, JP21ek0109511, JP22ek0109485, JP22ek0109468, JP22gk0110038, 23 JP19ek0109273), Program for Promoting Platform of Genomics based Drug Discovery 24 to Y.O. (Fund ID: JP22kk0305015), the Research Center Network for Realization of 25 Regenerative Medicine (The Acceleration Program for Intractable Diseases Research 26 utilizing Disease-specific iPS cells, JP21bm0804018), and JSPS KAKENHI JP19H03624 27 to Y.O. and JP20H03648 to H.O.

28

## 29 Author contributions

30 YK, AS and YO wrote the manuscript. YK, AS, TK, TE, TM, MS, NI, YN, HN, YY and YW 31 performed the experiments. YK, AS, TK, TE, TM, MS, NI, YN, HN, YY, AIO, YW and YO 32 analyzed the data. TK, TE, TM, MS, TF, HO, AO and KM acquired clinical information. 33 YK, AS, TF, KRN and AIO did bioinformatics and statistical analysis. YK, AS and AO 34 supervised the study. All authors discussed the results and commented on the 35 manuscript.

36

#### Disclosure and competing interests statement 1

2 The authors declare no competing interests.

3

### 1 References

2	Borna NN, Kishita Y, Kohda M, Lim SC, Shimura M, Wu Y, Mogushi K, Yatsuka Y,
3	Harashima H, Hisatomi Y, et al (2019) Mitochondrial ribosomal protein PTCD3
4	mutations cause oxidative phosphorylation defects with Leigh syndrome.
5	Neurogenetics 20: 9–25
6	Brechtmann F, Mertes C, Matusevičiūtė A, Yépez VA, Avsec Ž, Herzog M, Bader DM,
7	Prokisch H & Gagneur J (2018) OUTRIDER: A Statistical Method for Detecting
8	Aberrantly Expressed Genes in RNA Sequencing Data. Am J Hum Genet 103:
9	907–917
10	Burgin HJ & McKenzie M (2020) Understanding the role of OXPHOS dysfunction in the
11	pathogenesis of ECHS1 deficiency. FEBS Lett 594: 590–610
12	D'Annibale OM, Koppes EA, Alodaib AN, Kochersperger C, Karunanidhi A, Mohsen
13	AW & Vockley J (2021) Characterization of variants of uncertain significance in
14	isovaleryl-CoA dehydrogenase identified through newborn screening: An
15	approach for faster analysis. Mol Genet Metab 134: 29–36
16	D'Annibale OM, Koppes EA, Sethuraman M, Bloom K, Mohsen AW & Vockley J (2022)
17	Characterization of exonic variants of uncertain significance in very long-chain
18	acyl-CoA dehydrogenase identified through newborn screening. J Inherit Metab
19	Dis: 1–12
20	Findlay GM, Daza RM, Martin B, Zhang MD, Leith AP, Gasperini M, Janizek JD, Huang
21	X, Starita LM & Shendure J (2018) Accurate classification of BRCA1 variants with
22	saturation genome editing. Nature 562: 217–222
23	Haack TB, Jackson CB, Murayama K, Kremer LS, Schaller A, Kotzaeridou U, de Vries
24	MC, Schottmann G, Santra S, Büchner B, et al (2015a) Deficiency of ECHS1
25	causes mitochondrial encephalopathy with cardiac involvement. Ann Clin Transl
26	Neurol: n/a-n/a
27	Haack TB, Jackson CB, Murayama K, Kremer LS, Schaller A, Kotzaeridou U, de Vries
28	MC, Schottmann G, Santra S, Büchner B, et al (2015b) Deficiency of ECHS1
29	causes mitochondrial encephalopathy with cardiac involvement. Ann Clin Transl
30	Neurol: 492–509
31	Kohda M, Tokuzawa Y, Kishita Y, Nyuzuki H, Moriyama Y, Mizuno Y, Hirata T, Yatsuka
32	Y, Yamashita-Sugahara Y, Nakachi Y, et al (2016) A Comprehensive Genomic
33	Analysis Reveals the Genetic Landscape of Mitochondrial Respiratory Chain
34	Complex Deficiencies. PLoS Genet 12: 1–31
35	Kuwajima M, Kojima K, Osaka H, Hamada Y, Jimbo E, Watanabe M, Aoki S, Sato-
36	Shirai I, Ichimoto K, Fushimi T, et al (2021) Valine metabolites analysis in ECHS1

1 deficiency. Mol Genet Metab Reports 29 2 Kweon J. Jang AH, Shin HR, See JE, Lee W, Lee JW, Chang S, Kim K & Kim Y (2020) 3 A CRISPR-based base-editing screen for the functional assessment of BRCA1 4 variants. Oncogene 39: 30–35 5 Lee JS, Yoo T, Lee M, Lee Y, Jeon E, Kim SY, Lim BC, Kim KJ, Choi M & Chae JH 6 (2020) Genetic heterogeneity in Leigh syndrome: Highlighting treatable and novel 7 genetic causes. Clin Genet 97: 586-594 Naito Y, Hino K, Bono H & Ui-Tei K (2015) CRISPRdirect: Software for designing 8 9 CRISPR/Cas guide RNA with reduced off-target sites. Bioinformatics 31: 1120-10 1123 11 Ogawa E, Fushimi T, Ogawa-Tominaga M, Shimura M, Tajika M, Ichimoto K, 12 Matsunaga A, Tsuruoka T, Ishige M, Fuchigami T, et al (2020) Mortality of 13 Japanese patients with Leigh syndrome: Effects of age at onset and genetic diagnosis. J Inherit Metab Dis 43: 819–826 14 15 Ogawa E, Shimura M, Fushimi T, Tajika M, Ichimoto K, Matsunaga A, Tsuruoka T, 16 Ishige M, Fuchigami T, Yamazaki T, et al (2017) Clinical validity of biochemical 17 and molecular analysis in diagnosing Leigh syndrome: a study of 106 Japanese 18 patients. J Inherit Metab Dis 40: 685-693 19 Peters H, Buck N, Wanders R, Ruiter J, Waterham H, Koster J, Yaplito-Lee J, 20 Ferdinandusse S & Pitt J (2014) ECHS1 mutations in Leigh disease: A new inborn 21 error of metabolism affecting valine metabolism. Brain 137: 2903-2908 22 Peters H, Ferdinandusse S, Ruiter JP, Wanders RJA, Boneh A & Pitt J (2015) 23 Metabolite studies in HIBCH and ECHS1 defects: Implications for screening. Mol 24 Genet Metab 115: 168–173 25 Ran FA, Hsu PD, Wright J, Agarwala V, Scott DA & Zhang F (2013) Genome 26 engineering using the CRISPR-Cas9 system. Nat Protoc 8: 2281-2308 27 Richards S, Aziz N, Bale S, Bick D, Das S, Gastier-Foster J, Grody WW, Hegde M, 28 Lyon E, Spector E, et al (2015) Standards and guidelines for the interpretation of 29 sequence variants: A joint consensus recommendation of the American College of 30 Medical Genetics and Genomics and the Association for Molecular Pathology. 31 Genet Med 17: 405–424 32 Robinson BH, Petrova-Benedict R, Buncic JR & Wallace DC (1992) Nonviability of cells 33 with oxidative defects in galactose medium: A screening test for affected patient 34 fibroblasts. Biochem Med Metab Biol 48: 122–126 35 Sakai C, Yamaguchi S, Sasaki M, Miyamoto Y, Matsushima Y & Goto Y ichi (2015) 36 ECHS1 mutations cause combined respiratory chain deficiency resulting in leigh

1	syndrome. Hum Mutat 36: 232–239
2	Sato-Shirai I, Ogawa E, Arisaka A, Osaka H, Murayama K, Kuwajima M, Watanabe M,
3	Ichimoto K, Ohtake A & Kumada S (2021) Valine-restricted diet for patients with
4	ECHS1 deficiency: Divergent clinical outcomes in two Japanese siblings. Brain
5	Dev 43: 308–313
6	Sharpe AJ & McKenzie M (2018) Mitochondrial fatty acid oxidation disorders
7	associated with short-chain enoyl-CoA hydratase (ECHS1) deficiency. Cells 7: 1-
8	13
9	Simon MT, Eftekharian SS, Ferdinandusse S, Tang S, Naseri T, Reupena MS,
10	McGarvey ST, Minster RL, Weeks DE, Nguyen DD, et al (2021) ECHS1 disease
11	in two unrelated families of Samoan descent: Common variant - rare disorder. Am
12	J Med Genet Part A 185: 157–167
13	Stenton SL, Zou Y, Cheng H, Liu Z, Wang J, Shen D, Jin H, Ding C, Tang X, Sun S, et
14	al (2022) Leigh Syndrome: A Study of 209 Patients at the Beijing Children's
15	Hospital
16	Tadaka S, Hishinuma E, Komaki S, Motoike IN, Kawashima J, Saigusa D, Inoue J,
17	Takayama J, Okamura Y, Aoki Y, <i>et al</i> (2021) jMorp updates in 2020: Large
18	enhancement of multi-omics data resources on the general Japanese population.
19	Nucleic Acids Res 49: D536–D544
20	Tadaka S, Katsuoka F, Ueki M, Kojima K, Makino S, Saito S, Otsuki A, Gocho C,
21	Sakurai-Yageta M, Danjoh I, et al (2019) 3.5KJPNv2: an allele frequency panel of
22	3552 Japanese individuals including the X chromosome. Hum Genome Var 6
23	Tetreault M, Fahiminiya S, Antonicka H, Mitchell GA, Geraghty MT, Lines M, Boycott
24	KM, Shoubridge EA, Mitchell JJ, Michaud JL, <i>et al</i> (2015) Whole-exome
25	sequencing identifies novel ECHS1 mutations in Leigh syndrome. Hum Genet
26	134: 981–991
27	Uchino S, Iida A, Sato A, Ishikawa K, Mimaki M, Nishino I & Goto Y ichi (2019) A novel
28	compound heterozygous variant of ECHS1 identified in a Japanese patient with
29	Leigh syndrome. <i>Hum Genome Var</i> 6: 6–9
30	Vaca Jacome AS, Rabilloud T, Schaeffer-Reiss C, Rompais M, Ayoub D, Lane L,
31	Bairoch A, Van Dorsselaer A & Carapito C (2015) N-terminome analysis of the
32	human mitochondrial proteome. Proteomics 15: 2519–2524
33	Xia C, Lou B, Fu Z, Mohsen AW, Shen AL, Vockley J & Kim JJP (2021) Molecular
34	mechanism of interactions between ACAD9 and binding partners in mitochondrial
35	respiratory complex I assembly. iScience 24: 103153
36	Yamada K, Aiba K, Kitaura Y, Kondo Y, Nomura N, Nakamura Y, Fukushi D,

- 1 Murayama K, Shimomura Y, Pitt J, *et al* (2015) Clinical, biochemical and
- 2 metabolic characterisation of a mild form of human short-chain enoyl-CoA
- 3 hydratase deficiency: Significance of increased n-acetyl-s-(2-
- 4 carboxypropyl)cysteine excretion. *J Med Genet* 52: 691–698
- 5 Yang H & Yu D (2020) Clinical, biochemical and metabolic characterization of patients
- 6 with short-chain enoyl-CoA hydratase(ECHS1) deficiency: Two case reports and
- 7 the review of the literature. *BMC Pediatr* 20: 1–10
- 8

### 1 Figures

2

### 3 Figure 1. Summary of *ECHS1* variants

Gene structure (top) and corresponding amino acids (bottom) of *ECHS1*. Variants registered r as pathogenic (red) and likely pathogenic (yellow) in ClinVar, and jMorp (square) are shown. The two underlined variants were identified from our genomic analysis study; no experimental VUS verification was performed.

8

### 9 Figure 2. Characterization of *ECHS1* KO cells.

10 A. Genomic analysis of *ECHS1* KO cells by Sanger sequencing.

11 B. *EHCS1* expression levels in WT and *ECHS1* KO HEK293FT cells quantified by qRT-

PCR. Whole cell extracts from WT and *ECHS1* KO HEK293FT cells analyzed by immunoblotting using the indicated antibodies. Single and double asterisks indicate uncleaved and cleaved forms, respectively.

- 15 C. ATP assay of WT and *ECHS1* KO HEK293FT cells cultured in glucose or galactose
- 16 medium. The graph shows the ATP level in galactose medium divided by galactose.
- 17 D. ATP assay of WT and *ECHS1* KO HEK293FT cells treated with the indicated L-valine
- 18 concentrations. Bar graphs represent the average ATP level in each condition from three
- 19 biological independent experiments. Error bars, ±SEM. Statistical analysis was
- 20 performed using ANOVA followed by Dunnet's test. RLU, relative luciferase unit.
- 21

### 22 Figure 3. Validation of *ECHS1* VUS.

- WT and *ECHS1* KO HEK293FT cells transfected with the indicated expression vectors subjected to immunoblotting analysis (A) and ATP assay (B).
- A. Whole cell extracts were analyzed by immunoblotting using the indicated antibodies.
- 26 Single and double asterisks indicate uncleaved and cleaved forms, respectively.
- 27 B. ATP assay 4 days after treatment with L-valine (0.8 mM). Bar graphs represent the
- average ATP level in each condition from three biological independent experiments. Error
- <sup>29</sup> bars, ±SEM. Red bars, pathogenic variants. Gray bars, VUS. RLU, relative luciferase
- 30 unit.
- C. Statistical analysis of Figure B using ANOVA followed by Dunnet's test. The color scale shows the P value compared with vector (vs Vec, statistically different red to blue)
- and WT *ECHS1* (vs WT, statistically different blue to red).
- 34

### 35 Figure 4. Validation of ECHS1 VUS compound hetero.

A. Whole cell extracts from WT and *ECHS1* KO HEK293FT cells transfected with the

- 1 indicated expression vectors analyzed by immunoblotting using the indicated antibodies.
- 2 B. ATP assay of *ECHS1* KO HEK293FT cells expressing the indicated expression
- 3 vectors treated with additional L-valine (0.8 mM) for four days. Bar graphs represent the
- 4 average ATP level in each condition from three biological independent experiments. Error
- 5 bars, SEM. RLU, relative luciferase unit.
- 6 C. Statistical analysis of Figure B using ANOVA followed by Dunnet's test. The color
- 7 scale shows the P value compared with vector (vs Vec, statistically different red to blue)
- 8 and WT ECHS1 (vs WT, statistically different blue to red).
- 9

## 10 Figure 5. Abnormal splicing and allele-biased gene expression

- 11 A. RNA-seq data from two patients with c.489G>A (p.P163=) showing reads suggestive
- 12 of splicing abnormalities in exons with c.489G>A.
- 13 B. Read counts of the *ECHS1* gene are plotted on the horizontal axis and the number of
- 14 detected exon skipping is plotted on the vertical axis. Gene counts were calculated by
- 15 STAR, and the number of exon skipping was extracted from the Sashimi plot data.
- 16 C. Ratio of c.489G>A and c.796A>C and c.832G>A variants on the IGV viewer. In two
- 17 cases, the allele expression with c.489G>A was decreased.
- 18

## 19 Figure 6. ECHS1 protein status in the patient with Pro163= and Ala278Thr

- A. OUTRIDER analysis illustrating protein expression in a volcano plot. ECHS1 was
   detected as a protein with a large decrease in expression.
- 22 B. Western blotting for ECHS1 in patients with ECHS1 mutations and controls.
- 23 Compared to previously reported ECHS1 cases, case 1 showed significantly reduced
- ECHS1 expression.  $\beta$ -actin was detected as a loading control.
- 25

#### Tables 1

### 2

Patient	DNA	Protein(NP 004083.3)
	(NM_004092.4)	
0207	c.5C>T	p.Ala2Val
0207	c.176A>G	p.Asn59Ser
0255	c.176A>G	p.Asn59Ser
0255	c.413C>T	p.Ala138Val
0346ES	Sc.176A>G	p.Asn59Ser
0346ES	Sc.476A>G	p.Gln159Arg
0346YS	Sc.176A>G	p.Asn59Ser
0346YS	Sc.476A>G	p.Gln159Arg
0376	c.98T>C	p.Phe33Ser
0376	c.176A>G	p.Asn59Ser
0536	c.1A>G	p.Met1Val
0536	c.5C>T	p.Ala2Val
0775	c.5C>T	p.Ala2Val
0775	c.88+2T>C	
1038ES	Sc.5C>T	p.Ala2Val
1038ES	Sc.176A>G	p.Asn59Ser
1038YS	Sc.5C>T	p.Ala2Val
1038YS	Sc.176A>G	p.Asn59Ser
1135ES	c.5C>T	p.Ala2Val
1135ES	c.176A>G	p.Asn59Ser
1135YS	c.5C>T	p.Ala2Val
1135YS	c.176A>G	p.Asn59Ser
1553	c.5C>T	p.Ala2Val
1553	c.176A>G	p.Asn59Ser
2521	c.23T>C	p.Leu8Pro
2521	c.176A>G	p.Asn59Ser
2637	c.5C>T	p.Ala2Val
2637	c.176A>G	p.Asn59Ser
2816	c.23T>C	p.Leu8Pro
2816	c.176A>G	p.Asn59Ser

Table 1. ECHS1 variants identified from genomic analysis 3

4

Case	Sex	Onse	tSymptoms	Complex deficiency	OCR	Var 1	Var 2
1	female	> 1 y	poor suckling, metal acidosis	bolicCIV 26.1% (Fb)	<sup>0</sup> 68% (Fb)	c.796A>C (p.Thr266Pro)	c.489G>A )(p.Pro163=)
2	male	≤ 1 y	gait diso nystagmus, MR, abnormality	rder, Normal MRI (Fb)	N.T.	c.802G>A (p.Ala268Thr)	c.489G>A (p.Pro163=)
3	male	≤ 1 y	listlessness, me retardation, regres after exanth subitum, abnormality, deafn fatigue, hypotonia	ental ssion emaNormal MRI(Fb) ess,	36% (Fb)	c.832G>A (p.Ala278Thr)	c.489G>A (p.Pro163=)
4	male	> 1 y	developmental de convulsion, abnormalities, regression	elay, MRINormal (Fb)	54% (Fb)	c.832G>A (p.Ala278Thr)	c.489G>A (p.Pro163=)
5	male	> 1 y	Leigh syndro increase of 2-me 2,3-dihydroxybutyric acid	ome, thyl-Normal : (Fb)	58% (Fb)	c.833C>T (p.Ala278Val)	c.489G>A (p.Pro163=)

1

### 2 Table 2. Patient summary of cases with *ECHS1* variants

3 Fb: Fibroblast, CIV: Mitochondrial respiratory chain complex IV, OCR: oxygen

4 consumption rates. Complex enzyme activity was defined by <40% decrease. For OCR,

5 a value <71.6% was used as diagnostic criterion.

6



ClinVar Pathogenic ClinVar Likely pathogenic jMorp Not verified in this study





С

	Vec	wт	M1V	M1T	A2V	L8P	F33S	N59S	D63N	K74E	H119Q	L145P	P163L	T266P	A268T	R272Q	A278T
vs Vec	-	0.0015	0.6909	0.9888	0.9008	0.2205	0.0089	0.9997	0.0246	<0.0001	0.6735	0.9309	0.4297	0.0077	0.4514	0.0583	0.9953
vs WT	0.0015	-	0.0762	0.0158	0.0351	0.3391	0.999	0.0027	0.956	0.4807	0.0803	<0.0001	0.1651	0.9991	0.1547	0.7744	0.0002
Deleterious											S	E	Benigr				



С

	Vec	ωт	A2V	L8P	F33S	N59S	N59S+ Vec	N59S+ WT	N59S+ A2V	N59S+ L8P	N59S+ F33S
vs Vec		0.0001	0.2601	0.0031	0.0001	0.6689	0.9541	0.0003	0.3122	0.1256	0.0639
vs WT	0.0001		0.0008	0.0916	0.9895	0.0002	0.0001	0.4773	0.0006	0.0021	0.0047
Deleterious E											Benign

# А



В



С



c.796A>C(q.133,364,669T>G)



Case 4 c.489G>A(g.133,368,948C>T)



c.832G>A(g.133,362,909C>T)





В



Figure 6